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Purpose of the study
To evaluate the efficacy and safety of induction with enfu-
virtide (ENF) + antiretroviral (ARV) optimized back-
ground (OB) and maintenance with ENF + OB vs.
dropping ENF in moderate virological failure patients
requiring therapeutic change.
Methods
A prospective, non-inferiority, open-label multicenter
trial including patients pretreated with two or three classes
of ARV, viral load (VL) = 3 to 5.5 log10 HIV-1 RNA copies/
ml and possible ARV optimized background with at least
two active compounds. Patients were randomized 1:1
between the groups (ENF + OB, OB) after 28 weeks of
induction with ENF + OB for patients achieving VL<400
copies/ml at week 16, and VL<50 copies/ml at week 24.
The primary end-point was proportion of patients with
VL< 50 copies/ml at week 52.
Summary of results
84 patients included (37 centers), 80% male, 33% with
AIDS. Mean duration of previous ARV treatment = 10 +/-
4 years. At inclusion, median VL = 4.3 log10 copies/ml,
median CD4 = 259 cells/mm3 (<200 CD4/mm3: 32%).
Number of fully active ARV in the OB (GSS) was = 2 for
74% of patients (according to genotypic resistance test
performed at selection combined with all previous
selected mutations). At week 4, a reduction of VL >1 log10
was observed in 92% of patients and a reduction of VL >2
log10 vas obtained in 42% (74% in patients with VL =
30,000 copies/ml at inclusion). Median reduction of VL at
week 4 and week 24 were 1,9 log10 and 2,3 log10, respec-
tively. Adequate ENF concentrations (>1,000 ng/ml) were
observed in 80% of patients at week 4. At week 24, 69%
of patients reached VL< 50 copies/ml regardless of GSS.
Median increase from baseline in CD4 cells at week 4 and
week 24 were 25/mm3 and 71/mm3, respectively. At
week 52 within 45 randomized patients, 67% (16/24) in
the ENF + OB arm and 57% (12/21) in the OB arm
achieved VL< 50 copies/ml without failure after randomi-
zation. Median increase in CD4 from week 28 to week 52
were +18/mm3 in ENF + OB arm and -9/mm3 in OB arm.
56% of patients presented at least one injection site reac-
tion (ISR) with no influence observed of CD4 count, VL,
or lipodystrophy.
Conclusion
Addition of ENF to OB led to fast and good virological
response (at least 2 log drop in VL observed in 74% of
patients with initial VL >30,000 copies/ml at week 4).
During maintenance phase, in this population with a
smaller than planned number of patients, we cannot con-
clude as to the non-inferiority of OB vs. ENF + OB at week
52.
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